USDA licenses long-acting injectable for canine allergic dermatitis

With a 75-day dosing interval, the monoclonal antibody (mAb) treatment helps reduce the number of clinic visits required for managing allergic dermatitis and lower the risk of missed doses.

Zoetis Inc. announced that the U.S. Department of Agriculture (USDA) has licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs. The monoclonal antibody (mAb) is administered by subcutaneous injection every 75 days as needed, reportedly providing the longest dosing interval among licensed mAb treatments for canine allergic dermatitis.

Dog scratching himself behind his ear on green field** Note: Soft Focus at 100%, best at smaller sizes
Bigstockphoto

Cytopoint Plus targets and neutralizes interleukin-31 (IL-31), a molecule involved in transmitting itch signals in dogs with allergic dermatitis. Its extended dosing interval may reduce the frequency of clinic visits and help address treatment adherence challenges for dogs requiring long-term management.

Beyond skin irritation, chronic allergic itch can affect a dog's sleep, behavior, and social interactions.

"Frequent vet clinic visits for treating allergic dermatitis can create scheduling hurdles for busy pet caregivers, which may contribute to missed treatments and flare-ups," says Lindsay McKay, DVM, DACVD, at Animal Dermatology Group in a statement to Zoetis. "Cytopoint Plus directly addresses this challenge, extending the duration of relief from allergic itch through a manageable, convenient treatment routine."

The extended interval may offer greater convenience for owners and reduce treatment-related stress for dogs that find frequent veterinary visits difficult. It may also provide veterinary teams with another option when developing individualized treatment plans, including for families managing the ongoing costs and logistics of chronic allergic dermatitis care.

Cytopoint Plus expands the available treatment options for canine allergic itch. Zoetis' existing dermatology portfolio includes Cytopoint and the oral medications Apoquel and Apoquel Chewable.

Comments
Post a Comment

Comments